EP3509636A4 - Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns - Google Patents
Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns Download PDFInfo
- Publication number
- EP3509636A4 EP3509636A4 EP17848290.7A EP17848290A EP3509636A4 EP 3509636 A4 EP3509636 A4 EP 3509636A4 EP 17848290 A EP17848290 A EP 17848290A EP 3509636 A4 EP3509636 A4 EP 3509636A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cns
- injury
- disease
- activity
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000027418 Wounds and injury Diseases 0.000 title 1
- 230000006378 damage Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 208000014674 injury Diseases 0.000 title 1
- 210000003289 regulatory T cell Anatomy 0.000 title 1
- 230000009885 systemic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP23184844.1A EP4269439A3 (en) | 2016-09-10 | 2017-09-08 | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2016/001433 WO2017042633A2 (en) | 2015-09-10 | 2016-09-10 | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
US15/261,945 US10519237B2 (en) | 2014-03-12 | 2016-09-10 | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
PCT/IL2017/051011 WO2018047178A1 (en) | 2016-09-10 | 2017-09-08 | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23184844.1A Division EP4269439A3 (en) | 2016-09-10 | 2017-09-08 | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3509636A1 EP3509636A1 (en) | 2019-07-17 |
EP3509636A4 true EP3509636A4 (en) | 2020-12-16 |
Family
ID=61561788
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17848290.7A Withdrawn EP3509636A4 (en) | 2016-09-10 | 2017-09-08 | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
EP23184844.1A Pending EP4269439A3 (en) | 2016-09-10 | 2017-09-08 | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23184844.1A Pending EP4269439A3 (en) | 2016-09-10 | 2017-09-08 | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP3509636A4 (en) |
JP (2) | JP7074662B2 (en) |
KR (1) | KR20190050931A (en) |
CN (2) | CN108348607B (en) |
AU (1) | AU2017322656B2 (en) |
CA (1) | CA2997578A1 (en) |
IL (3) | IL300982B1 (en) |
MX (1) | MX2018003028A (en) |
WO (1) | WO2018047178A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
CN116640214A (en) | 2016-08-09 | 2023-08-25 | 科马布有限公司 | Isolated antibodies and uses thereof |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
EP3801571A4 (en) * | 2018-05-25 | 2022-08-10 | Memorial Sloan Kettering Cancer Center | Diagnosis and treatment of immunotherapy-induced neurotoxicity |
AU2019324170A1 (en) | 2018-08-23 | 2021-02-18 | Seagen, Inc. | Anti-TIGIT antibodies |
CN111956799A (en) * | 2020-09-18 | 2020-11-20 | 生物抗素公司 | Application of anti-PD-1 antibody and/or PD-L1 antibody in preparation of medicine for treating Parkinson's disease |
CN112569351B (en) * | 2020-12-16 | 2021-10-15 | 南通大学 | Application of CD44 antibody in preparing medicine for treating Parkinson's disease |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017040301A1 (en) * | 2015-08-28 | 2017-03-09 | Alector Llc | Anti-siglec-7 antibodies and methods of use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050106586A1 (en) * | 2003-06-13 | 2005-05-19 | Mount Sinai Hospital | Detection of neurodegenerative diseases |
CN1838950A (en) * | 2003-06-23 | 2006-09-27 | 神经化学(国际)有限公司 | Methods for treating protein aggregation disorders |
JP2007507430A (en) * | 2003-10-10 | 2007-03-29 | メディテック リサーチ リミテッド | Modulation of hyaluronan synthesis and degradation in the treatment of disease |
CA2791930A1 (en) * | 2010-03-11 | 2011-09-15 | Kerry Louise Tyson | Pd-1 antibody |
CN102492038B (en) | 2011-12-09 | 2014-05-28 | 中国人民解放军军事医学科学院基础医学研究所 | Anti-human Tim-3 neutralized monoclonal antibody L3D and application thereof |
EP3013355B1 (en) * | 2013-06-25 | 2019-08-07 | ICM - Institut du Cerveau et da la Moelle Epinière | Il-2 for use in treating alzheimer disease and related disorders |
WO2017042633A2 (en) * | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
US9394365B1 (en) * | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
CN114081946A (en) * | 2014-03-12 | 2022-02-25 | 耶达研究与开发有限公司 | Treatment of CNS diseases and injuries by reducing the level or activity of systemic regulatory T cells |
TWI664190B (en) * | 2014-06-27 | 2019-07-01 | 美商C2N醫療診斷有限責任公司 | Humanized anti-tau antibodies |
-
2017
- 2017-09-08 KR KR1020187010034A patent/KR20190050931A/en not_active IP Right Cessation
- 2017-09-08 CA CA2997578A patent/CA2997578A1/en active Pending
- 2017-09-08 CN CN201780003867.4A patent/CN108348607B/en active Active
- 2017-09-08 WO PCT/IL2017/051011 patent/WO2018047178A1/en active Application Filing
- 2017-09-08 MX MX2018003028A patent/MX2018003028A/en unknown
- 2017-09-08 EP EP17848290.7A patent/EP3509636A4/en not_active Withdrawn
- 2017-09-08 AU AU2017322656A patent/AU2017322656B2/en active Active
- 2017-09-08 CN CN202310632161.1A patent/CN116492457A/en active Pending
- 2017-09-08 EP EP23184844.1A patent/EP4269439A3/en active Pending
- 2017-09-08 JP JP2018512191A patent/JP7074662B2/en active Active
- 2017-09-08 IL IL300982A patent/IL300982B1/en unknown
-
2018
- 2018-03-05 IL IL257885A patent/IL257885B/en unknown
-
2022
- 2022-03-29 IL IL291784A patent/IL291784B2/en unknown
- 2022-05-12 JP JP2022078512A patent/JP7451596B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017040301A1 (en) * | 2015-08-28 | 2017-03-09 | Alector Llc | Anti-siglec-7 antibodies and methods of use thereof |
Non-Patent Citations (2)
Title |
---|
E. D. HUEY ET AL: "A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia", NEUROLOGY, vol. 66, no. 1, 9 January 2006 (2006-01-09), pages 17 - 22, XP055092755, ISSN: 0028-3878, DOI: 10.1212/01.wnl.0000191304.55196.4d * |
JOSEPHS ET AL: "Argyrophilic grains: A distinct disease or an additive pathology?", NEUROBIOLOGY OF AGING, TARRYTOWN, NY, US, vol. 29, no. 4, 3 March 2008 (2008-03-03), pages 566 - 573, XP022509460, ISSN: 0197-4580, DOI: 10.1016/J.NEUROBIOLAGING.2006.10.032 * |
Also Published As
Publication number | Publication date |
---|---|
WO2018047178A1 (en) | 2018-03-15 |
IL291784B2 (en) | 2023-09-01 |
KR20190050931A (en) | 2019-05-14 |
MX2018003028A (en) | 2018-05-28 |
IL257885A (en) | 2018-06-28 |
EP3509636A1 (en) | 2019-07-17 |
CA2997578A1 (en) | 2018-03-10 |
CN108348607A (en) | 2018-07-31 |
IL291784A (en) | 2022-06-01 |
IL291784B1 (en) | 2023-05-01 |
IL257885B (en) | 2022-05-01 |
CN108348607B (en) | 2023-06-23 |
JP7074662B2 (en) | 2022-05-24 |
IL300982B1 (en) | 2024-04-01 |
AU2017322656A1 (en) | 2018-04-19 |
CN116492457A (en) | 2023-07-28 |
EP4269439A3 (en) | 2024-01-17 |
JP7451596B2 (en) | 2024-03-18 |
JP2019530635A (en) | 2019-10-24 |
JP2022106983A (en) | 2022-07-20 |
IL300982A (en) | 2023-04-01 |
AU2017322656B2 (en) | 2024-02-29 |
EP4269439A2 (en) | 2023-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL256792A (en) | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns | |
EP3509636A4 (en) | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns | |
ZA201908165B (en) | Compounds for the prevention and treatment of diseases and the use thereof | |
EP3308793A4 (en) | Therapeutic agent for skin wound or rough skin | |
IL266047A (en) | Methods and compositions for the treatment of fabry disease | |
SG10201912134TA (en) | Methods and composition for the prediction of the activity of enzastaurin | |
PL3362449T3 (en) | Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis | |
EP3463324A4 (en) | Levocetirizine and montelukast in the treatment of radiation-mediated conditions | |
PT3481819T (en) | Compounds and their use for reducing uric acid levels | |
IL281585B (en) | Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof | |
HK1257236A1 (en) | Medicine for preventing and treating hyperlipemia diseases and use of the medicine | |
HK1257585A1 (en) | Medicine for preventing and treating skin fibrosis and use of the medicine | |
EP3253766A4 (en) | Compounds and methods for preventing or treating sensory hair cell death | |
AU2017267955B2 (en) | Reduced oxygen carriers and their use for the treatment of carboxyhemoglobinemia | |
IL272121A (en) | Composition and methods for the treatment of myopia | |
PT3389653T (en) | 2-iminobiotin for use in the treatment of brain cell injury | |
EP3374354A4 (en) | Benzofuran derivatives for the treatment of cns and other disorders | |
EP3697387A4 (en) | Combination of as1411 and sapc-dops for the treatment of glioblastoma multiforme | |
EP3308794A4 (en) | Therapeutic agent for skin wound or rough skin | |
EP3156054A4 (en) | Medicine for preventing and/or treating stress-induced diseases | |
EP3344337A4 (en) | Methods and compositions for the treatment of cytopplasmic glycogen storage disorders | |
EP3400025A4 (en) | The use of guaiacol for the prevention and treatment of glycogen storage disease | |
EP3302684A4 (en) | Methods and devices for treating the cornea | |
IL266726A (en) | Therapies for the treatment of lidocaine-ineffective and hypokalemic conditions | |
EP3371154A4 (en) | Heterocycle derivatives and their use for the treatment of cns disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180410 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 27/00 20060101ALI20200714BHEP Ipc: A61P 25/28 20060101ALI20200714BHEP Ipc: A61K 39/395 20060101AFI20200714BHEP Ipc: C07K 16/28 20060101ALI20200714BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20201117 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/28 20060101ALI20201111BHEP Ipc: A61P 27/00 20060101ALI20201111BHEP Ipc: A61K 39/395 20060101AFI20201111BHEP Ipc: C07K 16/28 20060101ALI20201111BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230103 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20230712 |